SFDA approves China Medical Technologies' SPR-based HPV-DNA chip

China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that it has received approval for its SPR-based HPV-DNA chip (the "HPV Chip") from the State Food and Drug Administration of China (the "SFDA").

Human papillomavirus ("HPV") is a common virus that infects the skin and mucous membranes of humans and causes various kinds of warts as well as cervical cancer. Over 100 HPV subtypes have been identified, in which 16 high risk HPV subtypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 81) may lead to the development of cervical cancer and 8 low risk HPV subtypes (6, 11, 40, 42, 43, 44, 54, 70) may lead to genital warts. The HPV Chip can detect the high risk genotypes as well as the low risk genotypes by placing a patient's sample on one chip and processing the chip by the Company's fully-automated SPR analyzer. The HPV Chip can also distinguish multiple HPV infection as well as determine the viral load which are all important for physicians to recommend treatment for patients.

According to the World Health Organization, China has a population of about 500 million women ages 15 years and older who are under the risk of cervical cancer. According to the Ministry of Health in China, approximately 70 million gynecological check-ups were conducted in 2008.